MarketInOut Stock Screener Log In | Sign Up

C4 Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
C4 Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization414.59 mln
Float113 mln
Earnings Date02/25/2027

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-1.88
Caution advised

1-Year Forecast

12.62
Transformational upside

Relative Strength

96 / 100
Top performer

Debt / Equity

0.23
Very low leverage

Pre-Tax Margin

-289%
Severely loss-making

Business Description

C4 Therapeutics is a clinical-stage drug discovery company focused on developing medicines that eliminate proteins responsible for causing disease. Its most advanced drug, Cemsidomide, is a tablet designed to treat multiple myeloma and has already completed early-stage human trials, while a second cancer drug targets a specific mutation seen in lung cancer patients. The company is also working on treatments for inflammatory and neurological conditions. Founded in 2015 and based in Watertown, Massachusetts, C4 Therapeutics works alongside major pharmaceutical partners including Roche, Merck KGaA, and Betta Pharmaceuticals to advance its pipeline.

Key Fundamentals

EPS-0.91
ROE-47.54
RPS0.31
ROIC-86.81
ROA-31.26
EBITDA, mln-93.83
EV / EBITDA-2.71
EV / EBIT-2.51
Revenue, mln35.04
EV / Revenue7.25

Quote Details

Last 3.37
Change 0.07 (2.12%)
Open 3.23
Volume 2,353,462
Turnover 7,931,166
Average Volume 2,840,172

Financial Ratios

Pre-Tax Profit Margin-289
Leverage Ratio1.45
Current Ratio5.45
Price / Book1.67
Price / Tangible Book1.68
Debt / Equity0.23
Price / Sales9.66

Financial Strength

Altman Z-Score-0.97
Piotroski F-Score 5 / 9
Beneish M-Score-1.88
1-Year Target Price12.62
Short Ratio17.84
Short % of Float34.93

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.13% 92 / 100   
1 Month 7.32% 82 / 100   
2 Months -6.13% 47 / 100   
6 Months 15.41% 78 / 100   
1 Year 34.26% 77 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog